Key result
Perioperative administration of landiolol significantly reduced the incidence of postoperative atrial fibrillation compared to control (19% vs. 37%, p=0.02).
Why the study?
Does perioperative landiolol reduce the incidence of postoperative atrial fibrillation in patients undergoing off-pump coronary artery bypass grafting?
Population
136 patients undergoing off-pump coronary artery bypass grafting
Comparison
Landiolol administered from the beginning of the… vs Non-landiolol (control)
Design
RCT, randomly assigned, single-blindly
Follow-up
7 days
Authors
Loading...
May support landiolol to lower POAF after off-pump CABG; hypothesis-generating and requires RCT confirmation before practice change.
RCT (n=136)
Single-blind
randomly
Does perioperative landiolol reduce the incidence of postoperative atrial fibrillation in patients undergoing off-pump coronary artery bypass grafting?
Absolute Event Rate: 19% vs 37%
p-value: p=0.02
Perioperative use of the short-acting beta-blocker landiolol significantly reduces the incidence of postoperative atrial fibrillation and inflammation in patients undergoing off-pump CABG.
Ogawa et al. (2013) conducted an RCT in off-pump coronary artery bypass grafting (n=136). Landiolol vs. Non-landiolol (control) was evaluated on Incidence of atrial fibrillation until postoperative day 7 (p=0.02). Perioperative administration of landiolol significantly reduced the incidence of postoperative atrial fibrillation compared to control (19% vs. 37%, p=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: